TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6091478
Drug: Ceftriaxone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (1 g every 12 hours)
Study: 6091478
Drug: Gentamicin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin (1 mg/kg every 8 hours) plus Clindamycin (8 mg/kg every 6 hours)
Study: 20851080
Drug: LEISH-F1+MPL-SE vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEISH-F1+MPL-SE vaccine (5, 10, or 20 μg recombinant Leishmania polyprotein LEISH-F1 antigen + 25 μg MPL(®)-SE adjuvant)
Study: 17611080
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of psychological treatment and anti-psychotic medication
Study: 16372586
Drug: Telmisartan titrated
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan titrated to 40 mg
Study: 16372586
Drug: Telmisartan titrated
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan titrated to 80 mg
Study: 12789723
Drug: AK‐2123 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK‐2123 (600 mg/m2 on alternate days)
Study: 12789723
Drug: Control (external
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (external radiation with telecobalt to a dose of 50 Gy and intracavitary radiation of 20 Gy)
Study: 11518092
Drug: Methylphenidate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (10 mg dose)
Study: 11518092
Drug: Methylphenidate (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (higher doses)
Study: 7962318
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg hydrocortisone hemisuccinate
Study: 7962318
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg hydrocortisone hemisuccinate
Study: 7962318
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg hydrocortisone hemisuccinate
Study: 12791621
Drug: Chewing gum
Normalized name: Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewing gum containing 1 mg nicotine and 0 mg caffeine
Study: 12791621
Drug: Chewing gum
Normalized name: Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewing gum containing 2 mg nicotine and 0 mg caffeine
Study: 12791621
Drug: Chewing gum
Normalized name: Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewing gum containing 1 mg nicotine and 50 mg caffeine
Study: 12791621
Drug: Chewing gum
Normalized name: Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewing gum containing 2 mg nicotine and 50 mg caffeine
Study: 12791621
Drug: Chewing gum
Normalized name: Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewing gum containing 1 mg nicotine and 100 mg caffeine
Study: 12791621
Drug: Chewing gum
Normalized name: Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewing gum containing 2 mg nicotine and 100 mg caffeine
Study: 12791621
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg nicotine and 0 mg caffeine)
Study: 1338387
Drug: Fluoxetine, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine, 60 mg daily for 14 days
Study: 24148020
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading of implants with a converted pre-existing denture on the day of surgery.
Study: 24148020
Drug: Delayed loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed loading of implants (control group) with soft-relined pre-existing denture.
Study: 17621644
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg daily (titrated to a maximum of 120 mg daily)
Study: 12560163
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro Mix25
Study: 10767227
Drug: Outpatient rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient rehabilitation program including 3 months of breathing retraining and chest physiotherapy, 3 months of daily supervised exercise, and 6 months of weekly supervised breathing exercises
Study: 21751299
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment acceptance
Study: 19189603
Drug: Bromocriptine (BRC)
DrugBank: Bromocriptine (DB01200)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bromocriptine (BRC) 1.25‐8.75 mg per day
Study: 16291415
Drug: Topiramate (25-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (25-600 mg/d for 26 weeks)
Study: 7572704
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g ethanol
Study: 1938771
Drug: Metaproterenol sulfate
Normalized name: Metaproterenol Sulfate
DrugBank: Orciprenaline (DB00816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metaproterenol sulfate (Alupent) metered dose inhaler
Study: 7006708
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow transplantation with cyclophosphamide (CY) 60 mg/kg/day for 2 days, 1000 rad total body irradiation, and a marrow transplant from a genotypically identical normal twin.
Study: 7006708
Drug: Immunotherapy consisting
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy consisting of killed autologous leukemic cells and/or normal twin peripheral blood lymphocytes.
Study: 7006708
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not specified, but includes patients who did not receive additional chemotherapy before CY).
Study: 25802961
Drug: Low-intensity wheelchair
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity wheelchair training (30%–40% heart rate reserve, twice a week, 30 mins per session for 16 weeks)
Study: 21434339
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment in Group F
Study: 3887394
Drug: Prophylactic anti-lymphocyte
Normalized name: lymphocyte immune globulin, anti-thymocyte globulin
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic anti-lymphocyte globulin (ALG) combined with azathioprine and steroids for 8.7 +/- 2.25 days after transplantation, followed by cyclosporine and steroids.
Study: 3887394
Drug: Azathioprine and
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine and steroids only (control group).
Study: 29338113
Drug: sacubitril/valsartan 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: sacubitril/valsartan 200 mg (97/103 mg)
Study: 24341948
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg metronidazole tablet (Flagyl®)
Study: 24341948
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of 15% metronidazole benzoate gel
Study: 19913119
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (single infusion)
Study: 19913119
Drug: Placebo (sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sodium chloride infusion)
Study: 10492054
Drug: Controlled-release oxycodone
Normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Controlled-release oxycodone 40 mg
Study: 10492054
Drug: Controlled-release morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release morphine 45 mg
Study: 10492054
Drug: Controlled-release morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release morphine 90 mg
Study: 8564100
Drug: Inhaled PGE2
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inhaled PGE2 (100 micrograms in 4 ml saline)
Study: 6988176
Drug: 0.25% desoxymethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% desoxymethasone in an oily cream base
Study: 6988176
Drug: 0.1% hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% hydrocortisone 17-butyrate cream
Study: 6988176
Drug: Oily cream
Normalized name: OILY CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oily cream base alone
Study: 28732523
Drug: Collabri model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collabri model for collaborative care (CC)
Study: 19230029
Drug: Intravenous glutathione
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glutathione 1,400 mg administered three times a week for 4 weeks
Study: 19230029
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered three times a week for 4 weeks
Study: 19230029
Drug: Intravenous glutathione
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glutathione 1,400 mg
Study: 15358690
Drug: bosentan (62.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: bosentan (62.5 mg b.i.d for 4 weeks then 125 mg b.i.d)
Study: 7525192
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination antihypertensive therapy
Study: 7525192
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination therapy
Study: 7525192
Drug: Thiazide diuretic
Normalized name: Thiazide diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide diuretic with potassium-sparing diuretic, β-blocker, or ACE inhibitor
Study: 7525192
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blocker with β-blocker or ACE inhibitor
Study: 627044
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg tartrazine
Study: 21197536
Drug: Levosimendan in
Normalized name: levosimendan Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan in addition to conventional heart failure therapy
Study: 21197536
Drug: Conventional heart
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional heart failure therapy (control group)
Study: 21197536
Drug: Levosimendan in
Normalized name: levosimendan Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan in addition to conventional therapy
Study: 19491859
Drug: Balsalazide 3.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balsalazide 3.3 g (1.1 g tablet, twice daily for 8 weeks)
Study: 16157113
Drug: High-dose vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vaginal misoprostol (600 microg x 1, then 400 microg every 4 hours x 5)
Study: 16157113
Drug: Concentrated intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated intravenous oxytocin plus low-dose vaginal misoprostol (oxytocin 277-1667 mU/min plus 400 microg x 1, then 200 microg every 6 hours x 2, then 100 microg x 1)
Study: 16157113
Drug: High-dose vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vaginal misoprostol
Study: 16157113
Drug: Concentrated intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated intravenous oxytocin plus low-dose vaginal misoprostol
Study: 2118322
Drug: Cefixime 400
Normalized name: cefixime 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime 400 mg daily, orally
Study: 2118322
Drug: Cephalexin 250
Normalized name: cephalexin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin 250 mg four times a day, orally
Study: 6112447
Drug: UK‐37 248
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK‐37 248 (200 mg)
Study: 23078148
Drug: Fluticasone/formoterol (100/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone/formoterol (100/10 μg b.i.d.)
Study: 7555622
Drug: Carbamazepine (CBZ),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (CBZ), titrated to 4-12 micrograms/ml
Study: 2208421
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of Scutellaria compound
Study: 2208421
Drug: Intravenous piperacillin
Normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous piperacillin sodium
Study: 24517055
Drug: TCM treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCM treatment group (combined A and B)
Study: 21639808
Drug: dacarbazine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: dacarbazine (1000 mg/m² intravenously every 3 weeks)
Study: 19853906
Drug: Liraglutide 2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 2.4 mg
Study: 19853906
Drug: Liraglutide 1.8-3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 1.8-3.0 mg
Study: 10965733
Drug: Propofol 1%
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 1% (10 mg/ml)
Study: 10965733
Drug: Propofol 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2% (20 mg/ml)
Study: 8911979
Drug: Glimepiride at
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glimepiride at a daily dose of 1-6 mg for 3 months in NIDDM patients with kidney disease
Study: 6509875
Drug: 0.9% sodium
Normalized name: LMD with 0.9% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride injection alone
Study: 6509875
Drug: Heparin 10
Normalized name: heparin 10 units/mL injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 10 units/ml in 0.9% sodium chloride injection
Study: 6509875
Drug: Heparin 100
Normalized name: heparin 100 units/mL injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 100 units/ml in 0.9% sodium chloride injection
Study: 28371815
Drug: FG-4592 low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: FG-4592 low-dose (1.1-1.75 mg/kg)
Study: 28371815
Drug: FG-4592 high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: FG-4592 high-dose (1.50-2.25 mg/kg)
Study: 28371815
Drug: FG-4592 low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: FG-4592 low-dose (1.1-1.8 mg/kg)
Study: 28371815
Drug: FG-4592 medium-dose
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FG-4592 medium-dose (1.5-2.3 mg/kg)
Study: 28371815
Drug: FG-4592 high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: FG-4592 high-dose (1.7-2.3 mg/kg)
Study: 28371815
Drug: FG-4592 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: FG-4592 (all doses)
Study: 28371815
Drug: FG-4592 high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: FG-4592 high-dose
Study: 21511749
Drug: ICRU point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICRU point doses in Group A (n=50)
Study: 16918716
Drug: L-arginine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (3 g daily)
Study: 11605012
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (including anthracycline and non-anthracycline based regimens)
Study: 9469687
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (Atrovent) nebulizer solution with BAC and EDTA
Study: 9469687
Drug: Albuterol nebulizer
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol nebulizer solution with BAC
Study: 9469687
Drug: EDTA in
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDTA in nebulizer solutions
Study: 9469687
Drug: Preservative-free bronchodilator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-free bronchodilator nebulizer solutions
Study: 125068
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 1.5% aqueous solution of 6-aminonicotinamide for four weeks
Study: 24895097
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy indicated by current guidelines
Study: 23937923
Drug: 10mg intravenous
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg intravenous dexamethasone intraoperatively
Study: 23937923
Drug: 24-hour postoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24-hour postoperative dose of 10mg intravenous dexamethasone
Study: 18650033
Drug: Open label
Normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open label sustained-release bupropion (300 mg/day) with gain-framed messages
Study: 18650033
Drug: Open label
Normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open label sustained-release bupropion (300 mg/day) with loss-framed messages
Study: 16858180
Drug: Iloprost (intra-arterial,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloprost (intra-arterial, intraoperative bolus of 3000 ng, plus intravenous infusion of 0.5-2.0 ng/kg/min for 6 hours/day for 4-7 days following surgery)
Study: 12460133
Drug: 9-session cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-session cognitive behavioral treatment (CBT) with motivational enhancement therapy (MET) and case management (CM) components
Study: 2024858
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (high-dose steroid therapy plus cyclophosphamide therapy for 8 weeks)
Study: 2024858
Drug: Plasmapheresis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasmapheresis treatment (12 plasmapheresis procedures during the first 4 weeks)
Study: 6724070
Drug: Liquid nitrogen
DrugBank: Nitrogen (DB09152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liquid nitrogen (subsequent treatment)
Study: 30962877
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual plus manual therapy (5 sessions, 30 min each)
Study: 30962877
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual plus manual therapy
Study: 26755593
Drug: MF59-adjuvanted trivalent
Normalized name: Influenza, adjuvanted, trivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted trivalent inactivated influenza vaccine (ATIV)
Study: 23774008
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) for childhood OCD, 12-session course
Study: 23774008
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) for childhood OCD
Study: 22926289
Drug: Naftopidil 25
Normalized name: Naftopidil
DrugBank: Naftopidil (DB12092)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Naftopidil 25 mg/day
Study: 22926289
Drug: Naftopidil 25
Normalized name: Naftopidil
DrugBank: Naftopidil (DB12092)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Naftopidil 25 mg/day plus tolterodine 2 mg (twice a day)
Study: 10521751
Drug: Morning meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning meal administered at 7 AM after a fast of ≥5 hours
Study: 10521751
Drug: Evening meal
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening meal administered at 9 PM after a fast of ≥5 hours
Study: 31022892
Drug: Iron folate
Normalized name: Iron Folate-F
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iron folate group (60 mg elemental iron and folate)
Study: 31022892
Drug: Folate group
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folate group (2.5 mg of folate)
Study: 26914455
Drug: Veratric acid
Normalized name: veratrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veratric acid (VA) cream applied topically; specific dosage and duration not mentioned.
Study: 22706571
Drug: IV iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV iron sucrose co-administered with IV Vitamin C (IS + C)
Study: 20130877
Drug: Docetaxel and
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel and cisplatin (75 mg/m2 every 3 weeks)
Study: 20130877
Drug: Docetaxel and
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel and cisplatin with radiation therapy (RT; 45 Gy)
Study: 18040014
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) at a mean dose of 2000 mg/day
Study: 18040014
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) at a mean dose of 564 mg/day
Study: 18040014
Drug: Non-drug
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-drug
Study: 15656813
Drug: Once-daily use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily use of topical corticosteroids
Study: 15656813
Drug: More frequent
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More frequent use of topical corticosteroids
Study: 15656813
Drug: Twice-daily treatment
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily treatment with potent topical corticosteroids
Study: 15656813
Drug: Three times
Normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three times daily use of very potent topical corticosteroids
Study: 7491877
Drug: Dexfenfluramine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexfenfluramine (30 mg)
Study: 6809627
Drug: 10 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms of Neisseria meningitidis group Y and group W135 polysaccharide vaccine
Study: 6809627
Drug: 25 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 micrograms of Neisseria meningitidis group Y and group W135 polysaccharide vaccine
Study: 6809627
Drug: 50 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 micrograms of Neisseria meningitidis group Y and group W135 polysaccharide vaccine
Study: 6809627
Drug: 100 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 micrograms of Neisseria meningitidis group Y and group W135 polysaccharide vaccine